Meeting
2022 ASCO Genitourinary Cancers Symposium
Viable germ cell tumor and teratoma can be distinguished from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens by a combination of microRNA-371a-3p and 375-5p.
Authors
Tim Nestler
Department of Urology, University Hospital Cologne, Cologne, Germany
Tim Nestler , Lara Kremer , Melanie von Brandenstein , Barbara Koeditz , Pia Paffenholz , Martin Hellmich , David Pfister , Axel Heidenreich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 421)
DOI
10.1200/JCO.2022.40.6_suppl.421
Abstract #
421
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.
First Author: Ricardo Romao Nazario Leao
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour: A multicenter retrospective cohort study.
First Author: Luca Antonelli
Poster
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
First Author: Nirmish Singla
Poster
2024 ASCO Annual Meeting
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
First Author: Ahmed Bilal Khalid